Stock and bond investment ideas from hedge fund managers at the Absolute Return Symposium in New York.» Read More
Feb 4- Boston Scientific Corp on Tuesday reported higher-than-expected quarterly results, citing improving demand for its devices that manage irregular heart rhythms. Boston Scientific is also expected to benefit from the introduction of its S-ICD system.
Feb 4- Boston Scientific Corp on Tuesday reported higher-than-expected quarterly earnings on higher sales of its implantable devices that manage irregular heart rhythms. Boston Scientific forecast 2014 earnings of 75 cents to 80 cents a share, excluding special items, on revenue of $7.3 billion to $7.5 billion.
Feb 4- Boston Scientific Corp on Tuesday reported higher fourth-quarter earnings on stronger sales of its implantable devices that manage irregular heart rhythms. The medical device maker said it had earned $108 million, or 8 cents a share, compared with $60 million, or 4 cents a share, a year earlier.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Jan 21- Jan 21- Covidien Plc said it would stop making a device for treating high blood pressure due to weak demand for the product, raising more doubts about the future of the novel technology.
Stocks closed slightly lower on Monday, with the S&P 500 extending 2014 losses into a third session.
Some of Monday's midday movers:
Some of the names on the move ahead of the open.
Dec 11- An advisory panel of medical experts voted on Wednesday to recommend that U.S. health regulators approve an experimental stroke-prevention device made by Boston Scientific Corp. The FDA typically follows the recommendations of its expert advisory panels, but is not obligated to do so.
The FDA released documents about the device, called Watchman, ahead of a meeting on Wednesday of outside medical experts who will consider its risks and benefits and then recommend whether the FDA should approve the product for use in patients.
Dec 9- Boston Scientific Corp's anti-stroke device did not meet one measure of success in a clinical study of the implant, but other data must be considered when determining overall safety and effectiveness, staff members of the U.S. Food and Drug Administration stressed on Monday.
Some of Friday's midday movers:
Nov 19- Medtronic Inc reported higher quarterly earnings on Tuesday as stronger sales of its implantable devices to treat abnormal heart rhythms offset weakness in its spinal products business.
WASHINGTON, Nov 5- The U.S. Supreme Court on Tuesday heard arguments in a case of warring legal doctrines raised by a heart pacemaker patent fight between giant medical devices company Medtronic Inc and privately owned Mirowski Family Ventures LLC.
*Expects 1st- quarter adj earnings $0.66/ shr vs est $0.65. Oct 30- Chipmaker Skyworks Solutions Inc forecast current-quarter results above analysts' estimates as it sells more analog chips used to connect machines to the Internet, sending its shares up 5 percent in extended trading.
WASHINGTON, Oct 29- Technology companies on Tuesday urged fast action on a patent reform bill in testimony before the House Judiciary Committee, including tackling what they termed the rising tide of costly lawsuits by "patent trolls."
Stocks are at record highs and Wall Street is getting feverishly bullish. What could possibly go wrong?
Oct 24- Boston Scientific Corp, which is in the midst of an attempted turnaround, reported weak sales of its heart stents and provided a disappointing fourth-quarter company sales forecast, sending its shares almost 7 percent lower on Thursday.
Oct 24- Boston Scientific Corp, which a day earlier announced a new round of job cuts, on Thursday reported a narrower third-quarter loss on flat sales of its array of medical devices. Excluding special items, including for new restructuring programs and litigation, Boston Scientific earned 10 cents per share.
The stocks moving before the bell.